Gritstone Oncology Inc (GRTS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Gritstone Oncology Inc stock (GRTS) is currently trading at $0.03. Gritstone Oncology Inc PS ratio (Price-to-Sales) is 0.26. Analyst consensus price target for GRTS is $1.00. WallStSmart rates GRTS as Sell.
- GRTS PE ratio analysis and historical PE chart
- GRTS PS ratio (Price-to-Sales) history and trend
- GRTS intrinsic value — DCF, Graham Number, EPV models
- GRTS stock price prediction 2025 2026 2027 2028 2029 2030
- GRTS fair value vs current price
- GRTS insider transactions and insider buying
- Is GRTS undervalued or overvalued?
- Gritstone Oncology Inc financial analysis — revenue, earnings, cash flow
- GRTS Piotroski F-Score and Altman Z-Score
- GRTS analyst price target and Smart Rating
Gritstone Oncology Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Gritstone Oncology Inc (GRTS) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Gritstone Oncology Inc (GRTS) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Gritstone Oncology Inc (GRTS) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -52.90%, a shrinking business
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Gritstone Oncology Inc (GRTS) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.26), Price/Book (0.21) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -52.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -201.90%, Operating Margin at -2995.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -201.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -52.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GRTS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GRTS's Price-to-Sales ratio of 0.26x sits near its historical average of 0.26x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 0.26x set in Feb 2026, and 0% above its historical low of 0.26x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Gritstone Oncology Inc (GRTS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Gritstone Oncology Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 15M with 53% decline year-over-year.
Key Findings
Spending 142% of revenue (21M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 53% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -27M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Gritstone Oncology Inc.
Bottom Line
Gritstone Oncology Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Gritstone Oncology Inc(GRTS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Gritstone bio, Inc., a clinical-stage biotechnology company, is dedicated to developing tumor-specific cancer immunotherapies to combat various types of cancer and infectious diseases. The company is headquartered in Emeryville, California.